Navigation Links
OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
Date:4/28/2009

atic castrate resistant prostate cancer showing better than expected survival results, reductions in levels of clusterin, durable reductions in pain, and a decline in PSA, a protein that is often elevated in patients with prostate cancer.

Based on clinical results to date, OncoGenex intends to conduct Phase 3 registration trials with OGX-011 in metastatic castrate resistant prostate cancer, subject to the receipt of additional funding. The U.S. Food & Drug Administration (FDA) has currently agreed on the design of two Phase 3 registration trials, via the Special Protocol Assessment (SPA) process, of OGX-011 in combination with second-line chemotherapy. One trial design investigates overall survival as the primary endpoint; the other trial design investigates pain palliation as the primary endpoint. OGX-011 has received Fast Track designation from the FDA for the treatment of progressive metastatic prostate cancer in combination with docetaxel.

OncoGenex holds an exclusive license for patents related to clusterin inhibition obtained from the University of British Columbia based on discoveries made by researchers at the Prostate Centre at Vancouver General Hospital. OGX-011 utilizes second-generation antisense technology, licensed from Isis Pharmaceuticals (NASDAQ: ISIS), to effectively target and inhibit production of clusterin protein in tumor cells. OncoGenex and Isis partnered in the successful discovery and initial development of OGX-011 and, in 2008, amended their agreement to provide OncoGenex with sole rights to OGX-011 and sole responsibility for development costs and partnering decisions, subject to financial obligations to Isis.

About the Special Protocol Assessment and Agreement Process

Under a Special Protocol Assessment (SPA), a company and the FDA can reach an agreement on the design and size of
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... , Dec. 15, 2014  Origin Agritech Limited (NASDAQ GS: ... technology-focused supplier of crop seeds in China ... its fiscal year 2014 ended September 30, 2014, before the ... Company will host a teleconference on January 8, 2015, at ... time to discuss the results. To participate in the ...
(Date:12/13/2014)... 12, 2014 The DNA Microarray ... 2013, and is expected to grow at a ... Browse through the TOC of the DNA Microarray ... and segments, with help of various tables and ... DNA Microarray market consists of instrument, consumables, and ...
(Date:12/13/2014)... , Dec. 12, 2014  Vermillion, Inc. (NasdaqCM: VRML), a ... the appointments of Veronica G. H. Jordan , ... Company,s Board of Directors, bringing the total number of ... Jim LaFrance , Chairman, President, and ... pleased to announce the appointments of Veronica and David ...
(Date:12/12/2014)... Graphite Metallizing Corporation, the manufacturer of self-lubricating ... equipment, has appointed Kirk Staller as Sales Engineering Representative ... holds a B.S. degree from Purdue University and has ... much of it with a manufacturer of centrifugal pumps. ... , “We are pleased to have Kirk ...
Breaking Biology Technology:Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 2Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 3DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 2DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 3DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 4Vermillion Strengthens Board of Directors with Appointments of Veronica Jordan, Ph.D., and David Schreiber 2Vermillion Strengthens Board of Directors with Appointments of Veronica Jordan, Ph.D., and David Schreiber 3Kirk Staller Joins Graphite Metallizing Corporation 2
... Definiens, the number one Health Image Intelligence™ company, and ... diagnostics, today announced a partnership to develop a unique ... will apply Definiens, image analysis technology to develop new ... a variety of cancer types. Cernostics is ...
... Inc., a subsidiary of Eisai Inc., announced today that it ... Care , a national support services organization for people affected ... programs for people facing lung and ovarian cancers.  The two ... families become aware of options available to help treat and ...
... 5, 2011) -- Using minute graphite particles 1000 times smaller ... Arizona State University hope to boost the efficiencyand profitabilityof solar ... more and more on rooftops, but they,re not necessarily the ... is that they can use only a fraction of the ...
Cached Biology Technology:Definiens and Cernostics Partner to Develop Multiplexed Cancer Diagnostic Tests 2Definiens and Cernostics Partner to Develop Multiplexed Cancer Diagnostic Tests 3Morphotek®, Inc. Receives Beacon Award From CancerCare 2Morphotek®, Inc. Receives Beacon Award From CancerCare 3Nanoparticles improve solar collection efficiency 2
(Date:12/11/2014)...  That blood pressure plays a role in human health ... medical term for high blood pressure – was first described ... cuff that,s used in measuring blood pressure was invented in ... about hypertension, its triggers and its effects. In fact, recent ... the best ways to treat it. For example, ...
(Date:12/10/2014)... WINSTON-SALEM, N.C. , Dec. 9, 2014  Wake Forest ... medical education building for its School of Medicine. Funding ... a larger capital campaign that will be publicly launched ... will be located in the former 60 series R.J. ... Forest Innovation Quarter. Construction will begin immediately with plans ...
(Date:12/5/2014)... VIEW, Calif. , Dec. 4, 2014 /PRNewswire/ ... safety has boosted investments in new testing and ... has also given rise to a range of ... by the requirements of Generation Y, which is ... technologies. As a result, product development strategies of ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4
... (NSU) is using part of a $10 million block grant ... impact on the marine ecosystem, officials announced this week. ... in Florida selected to work on 27 research projects that ... marine life. The projects were selected by the Florida Institute ...
... to a biological invader that reaches its shores via ... Zebra mussels, Asian Longhorned Beetles, Kudzu, Triffid weed and ... destroying agriculture, harming human health and threatening biodiversity. ... and cost of controlling invaders against the economic necessity ...
... BOZEMAN, Mont. - More than 120 sturgeon and paddlefish ... 31 through Sept. 2 in Bozeman and at Chico ... annual meeting of the North American Chapter of the World ... study sturgeon and paddlefish in North America. The meeting ...
Cached Biology News:NSU scientists receive BP money to research oil spill's impact 2New analysis weighs lost trade, costs to control invasive species against economic damages 2New analysis weighs lost trade, costs to control invasive species against economic damages 3
Mycoplasma Removal Agent (MRA) has been developed for cell culture, to combat the widespread problems caused by contamination of cell cultures with mycoplasma....
albumin from bovine serum (BSA), 2,4-dinitrophenylated (DNP-BSA)...
Request Info...
albumin from bovine serum (BSA), Alexa Fluor® 647 conjugate...
Biology Products: